Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

14.3%

1 terminated/withdrawn out of 7 trials

Success Rate

85.7%

-0.8% vs industry average

Late-Stage Pipeline

14%

1 trials in Phase 3/4

Results Transparency

17%

1 of 6 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

N/A

3(42.9%)

Phase 2

3(42.9%)

Phase 4

1(14.3%)

7Total

N/A(3)

Phase 2(3)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT06135337Not ApplicableCompleted

THIODERM ELATE for Augmentation of Very Thin, Thin, and Moderately Thick Lips

Role: collaborator

NCT06128109Not ApplicableCompleted

THIODERM STRONG Compared to Juvéderm® VOLUMA® Lidocaine for the Treatment of Midface Volume Deficit

Role: collaborator

NCT06133153Not ApplicableWithdrawn

THIODERM ELATE for Volume Augmentation in Lips

Role: collaborator

NCT03749148Phase 2Completed

Cholinergic Urticaria - Efficacy of Dupilumab

Role: collaborator

NCT03749135Phase 2Completed

Dupilumab in Chronic Spontaneous Urticaria

Role: collaborator

NCT02589405Phase 4Completed

Benzac 5% Gel in Combination With Cosmetic Products in Acne Vulgaris

Role: collaborator

NCT03592342Phase 2Completed

Intra-oral Treatment of OLP With Rivelin®-CLO Patches

Role: collaborator

All 7 trials loaded